pitavastatin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 50 Diseases   20 Trials   20 Trials   1114 News 


12345678910111213...1415»
  • ||||||||||  Journal:  Clinical Evaluation of Drug-Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent. (Pubmed Central) -  Apr 12, 2025   
    Famotidine (gastric acid suppression) coadministration decreased GS-441524 exposure by approximately 26%; this was within the range of exposures observed in previous Phase III studies and was considered not clinically relevant...These findings indicate that obeldesivir has low potential for drug-drug interactions. Obeldesivir remains a promising treatment against a broad spectrum of viruses given its antiviral activity and favorable safety profile.
  • ||||||||||  Journal:  Transport of statins by multidrug resistance-associated proteins 1 and 5. (Pubmed Central) -  Mar 16, 2025   
    Atorvastatin was only a weak substrate of MRP5 with an uptake ratio of 1.6 and was therefore not investigated further...Pravastatin, rosuvastatin, and simvastatin acid were not transported by MRP1 or MRP5...These data indicate that MRP1 transports fluvastatin, while MRP5 transports both fluvastatin and pitavastatin. Because MRP1 and MRP5 are expressed in the skeletal muscle, they may reduce myocyte exposure to fluvastatin and pitavastatin and protect from muscle toxicity.
  • ||||||||||  atorvastatin / Generic mfg., pitavastatin / Generic mfg.
    INFLUENCE OF STATIN POTENCY AND LIPOSOLUBILITY ON ALZHEIMER () -  Mar 10, 2025 - Abstract #ADPD2025ADPD_1158;    
    A potential association between statins and the intake of AD medication has been observed. Specifically, low-potency (pitavastatin) and hydrophilic (rosuvastatin) statins were associated with less use of anti-AD medication.
  • ||||||||||  Journal:  Structural and functional implications of ABCC1 variants on clinical statin response. (Pubmed Central) -  Mar 9, 2025   
    Here, we evaluated specific non-synonymous (SNV) missense variants in the ABCC1 gene from a FH patient cohort, assessing potential impacts on protein structure, molecular dynamics and interactions with rosuvastatin, atorvastatin, pravastatin, pitavastatin, and lovastatin...Interestingly, diminished binding affinities hinted at a compensatory mechanism wherein other transporters might mitigate potential ABCC1 mutation effects, ensuring effective drug efflux. Clinical profiles from the patient cohort did not show a correlation between these variants and clinical outcomes, potentially pointing to the role of alternate drug transporters in statin interaction.
  • ||||||||||  Journal:  Embryotoxicity of Statins and other Prescribed Drugs with Reported Off-target Effects on Cholesterol Biosynthesis. (Pubmed Central) -  Mar 9, 2025   
    Our data show that statins are heterogenous with respect to their ability to cause embryonic lethality, with simvastatin, pitavastatin, lovastatin, cerivastatin, and fluvastatin being the most toxic ones...On the other hand, psychotropic drugs were less embryonic lethal than statins but caused similar phenotypes as well as microcephaly and holoprosencephaly. Our findings suggest that the proximal and distal inhibition of cholesterol biosynthesis have different but overlapping effects on embryonic development.
  • ||||||||||  LIPOPHILIC STATIN USE IS ASSOCIATED WITH A LOWER RISK OF HEPATOCELLULAR CARCINOMA IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)-RELATED CIRRHOSIS (Halls C-E, Lower Level - SDCC) -  Mar 8, 2025 - Abstract #DDW2025DDW_1282;    
    Propensity score matching was performed between the two cohorts, hydrophilic statin (rosuvastatin and pravastatin) versus lipophilic statin (simvastatin, fluvastatin, pitavastatin, lovastatin, and atorvastatin) and the hazard ratio (HR) and 95% confidence interval was calculated...After propensity score matching of 11 variables, including age, gender, race, BMI, history of diabetes, insulin or other oral diabetes medication, history of hypertension, ischemic heart disease, and aspirin use, 3,073 patients in each group were included in the final analysis...Conclusions : Lipophilic statins were associated with a lower risk of HCC in MASLD cirrhosis patients, but no association was found with the risk of hepatic decompensation. Further larger prospective studies need to explore the different efficacy of statins for the prevention of HCC and hepatic decompensation in MASLD cirrhosis patients.
  • ||||||||||  pitavastatin / Generic mfg.
    Statin Effect Heterogeneity on Plaque Volume and Composition in the REPRIEVE Mechanistic Substudy (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_1364;    
    Conclusions These exploratory results suggest pitavastatin effects on NCP vary by demographic and cardiovascular risk factors; modification of statin effects by HIV risk factors was not apparent. The effect of pitavastatin appears greatest in reducing volume of fibrofatty plaque, which is thought to be the most biologically active component, and may increase plaque density.
  • ||||||||||  pitavastatin / Generic mfg.
    Prognostic Factors of Physical Function Decline in the PREPARE Study (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_945;    
    Background The Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) substudy of REPRIEVE found small declines in physical function, and no evidence of pitavastatin effect...The sex difference was attenuated in models adjusted for BMI, history of depression treatment, and inflammatory markers, which were higher/more prevalent among females (1.16, 0.98-1.38 in females vs. males, when including hs-CRP). Conclusions PWH with history of depression, high BMI or levels of inflammation and those showing signs of impairment may benefit from early intervention strategies to preserve function with aging.
  • ||||||||||  pitavastatin / Generic mfg.
    No Evidence of a Detrimental Effect of Pitavastatin on Neurocognitive Function Among People With HIV (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_872;    
    Other subgroup effects were minimal and not statistically or clinically significant. Conclusions We found no evidence to suggest a detrimental effect of pitavastatin on a limited battery of neurocognitive assessments among people with HIV at low to moderate cardiovascular risk, even among those with baseline impairment.
  • ||||||||||  pitavastatin / Generic mfg.
    Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects (San Francisco Ballroom B) -  Mar 3, 2025 - Abstract #CROI2025CROI_296;    
    Further analysis using continuous FI suggested consistent pitavastatin effect across the spectrum of frailty. Conclusions Frailty was associated with markedly higher incidence of MACE, but did not appear to modify the protective effects of pitavastatin seen in the REPRIEVE primary analysis.
  • ||||||||||  pitavastatin / Generic mfg.
    Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy (San Francisco Ballroom B) -  Mar 3, 2025 - Abstract #CROI2025CROI_293;    
    This analysis suggests that the benefit of pitavastatin to prevent MACE may be greater in persons with preexisting plaque and baseline levels of subclinical myocardial injury. Further investigation is needed to determine whether plaque and/or biomarkers can help identify PWH at highest risk who would most benefit from statin prevention.
  • ||||||||||  pravastatin / Generic mfg., pitavastatin / Generic mfg.
    PK/PD data, Journal:  Identification of Genetic Variants Associated with Pravastatin and Pitavastatin Pharmacokinetics. (Pubmed Central) -  Mar 3, 2025   
    of pitavastatin than those with normal metabolizer CYP2C9 genotype. This study demonstrates the important role of SLCO1B1 in pravastatin and pitavastatin pharmacokinetics and suggests that CYP2C9 variants also affect the pharmacokinetics of pitavastatin.
  • ||||||||||  Journal:  The impact of statin use on sepsis mortality. (Pubmed Central) -  Mar 2, 2025   
    This study demonstrates the important role of SLCO1B1 in pravastatin and pitavastatin pharmacokinetics and suggests that CYP2C9 variants also affect the pharmacokinetics of pitavastatin. Statin use is associated with improved outcomes following sepsis-related intensive care unit (ICU) admission, most likely from its pleiotropic properties, characterized by lower 90-day and in-hospital mortality among statin users.
  • ||||||||||  atorvastatin / Generic mfg., rosuvastatin / Generic mfg., pitavastatin / Generic mfg.
    Journal:  The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus. (Pubmed Central) -  Feb 26, 2025   
    In patients with T2DM, statin use did not show a significant effect on the liver fat fraction, but it caused differences in the pancreatic fat fraction. The observation of a lower pancreatic fat fraction in patients taking a rosuvastatin and atorvastatin dose of 40 mg/day suggests that different types and doses of statins may have varying effects on pancreatic fat accumulation.
  • ||||||||||  Observational data, Retrospective data, Journal:  Effect of prior use of statins on endovascular thrombectomy outcomes in acute ischemic stroke. (Pubmed Central) -  Feb 25, 2025   
    Statin use within 3 months prior to AIS was associated with better survival and lesser intracranial bleeding risks and complications following EVT. Future studies may help examine how the duration or dosages of statins or LDL levels on admission affect outcomes in LVO strokes treated with EVT.
  • ||||||||||  SQ-109 / Sequella, pitavastatin / Generic mfg.
    Journal:  Broad-Spectrum Activity and Mechanisms of Action of SQ109 on a Variety of Fungi. (Pubmed Central) -  Feb 20, 2025   
    SQ109 disrupted H + /Ca 2+ homeostasis in S. cerevisiae vacuoles, and there was synergy (FICI?0.31) with pitavastatin, indicating involvement of isoprenoid biosynthesis pathway inhibition. SQ109 is, therefore, a potential antifungal agent with multi-target activity.
  • ||||||||||  atorvastatin / Generic mfg., rosuvastatin / Generic mfg., pitavastatin / Generic mfg.
    Retrospective data, Journal:  Statin Use and the Risk of Graves' Orbitopathy: A Nationwide Population-Based Cohort Study. (Pubmed Central) -  Feb 11, 2025   
    The use of statins in Asian GD patients was associated with a reduced risk of GO. In addition, the risk of developing GO among users of commonly prescribed statins or users of different intensities of statins was not significantly different.
  • ||||||||||  temozolomide / Generic mfg., pitavastatin / Generic mfg.
    Journal:  Are we better together? Addressing a combined treatment of pitavastatin and temozolomide for brain cancer. (Pubmed Central) -  Dec 9, 2024   
    The obtained qRT-PCR and proteomics data highlight the modulation of cell death via apoptosis (BAX/BCL2, CASP9) and autophagy (BECN1, BNIP3, BNIP3L and LC3B), as well as an epithelial to mesenchymal transition blockage (HTRA1, SERPINE1, WNT5A, ALDH3B1 and EPHA2) and remodeling of the extracellular matrix (VCAN, SERPINE1 and TGFBI). Overall, these results lay the foundation for further investigations on the potential combinatory clinical treatment with temozolomide.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie
    Pitavastatin Potentiates Mitochondrial Dysfunction and Venetoclax Cytotoxicity in Acute Myeloid Leukemia Cells () -  Dec 7, 2024 - Abstract #ASH2024ASH_7893;    
    P1
    Notably, PIT sensitizes AML cells to venetoclax by upregulating PUMA via a p53-independent mechanism and by reducing mitochondrial fitness. These results demonstrate that targeting the mevalonate pathway with PIT in combination with venetoclax might be effective to overcome resistance, increase survival and improve clinical outcome.
  • ||||||||||  ezetimibe / Generic mfg., pitavastatin / Generic mfg.
    Journal:  NIR-Guided Coating Optimization of Omega-3 Fatty Acid Mini Soft Capsules with Pitavastatin and Ezetimibe. (Pubmed Central) -  Nov 27, 2024   
    The application of NIR spectroscopy for real-time monitoring highlights its broader significance in pharmaceutical manufacturing, where it can serve as a versatile tool for ensuring product quality and optimizing production efficiency in diverse formulation processes. By incorporating NIR-based PAT, manufacturers can not only achieve product-specific improvements but also establish a foundation for continuous manufacturing and automated quality assurance systems, ultimately contributing to a more streamlined and robust production environment.
  • ||||||||||  ezetimibe / Generic mfg., pitavastatin / Generic mfg.
    Journal:  Rapid lipid-lowering response in two cases of autosomal recessive hypercholesterolemia. (Pubmed Central) -  Nov 14, 2024   
    Our findings demonstrate a rapid and significant response to lipid-lowering therapy (LLT) in patients with ARH caused by c.617-14C>A splicing VUS variant, a condition that mimics HoFH at diagnosis. Long-term follow-up studies in large pediatric cohorts of ARH patients treated with pitavastatin plus ezetimibe from childhood are necessary to better define the risk of cardiovascular disease (CVD) development.